Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 3:12:1179546818796482.
doi: 10.1177/1179546818796482. eCollection 2018.

Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study

Fernando Manzur  1 , Andrés Rico  2 , Juan Diego Romero  3 , Carlos E Rodriguez-Martinez  4
Affiliations

Efficacy and Safety of Valsartan or Chlorthalidone vs. Combined Valsartan and Chlorthalidone in Patients With Mild to Moderate Hypertension: The VACLOR Study

Fernando Manzur et al. Clin Med Insights Cardiol. .

Abstract

Objective: To evaluate the efficacy and safety of valsartan (V) or chlorthalidone (C) monotherapy in comparison with a fixed combination of valsartan and chlorthalidone (V + C).

Methods: This 12-week multicenter randomized three-arm open-label study randomly allocated 72 patients to V or C as monotherapy or a combination of V + C. The aim was to measure changes in office systolic blood pressure (SBP) and diastolic blood pressure (DBP) and in 24-hour ambulatory blood pressure monitoring (ABPM) from baseline to week 12, in addition to medication tolerability.

Results: The proportion of patients achieving target BP in office at week 12 was not statistically different for the three groups. However, comparisons of daytime and nighttime 24-hour ABPM values from baseline to week 12 revealed significant differences in nighttime mean SBP for the three groups, due to a significantly greater reduction in the values in patients assigned to the V + C group (-14.7 vs. -8.7 vs. -10.7, P = .042, V+C; V; C, respectively). Although patients assigned to the V + C group also had greater nighttime reduction in mean DBP values compared with those in the other groups, this difference was not statistically significant. The incidence of adverse events did not differ significantly.

Conclusion: In patients with hypertension treated with V, C, and both medications combined, the fixed combination of V + C provided a significantly greater reduction of late night to early morning BP values when interventions were assessed with 24-hour ABPM.

Trial registration: clinicaltrials.gov Identifier: NCT.01850160, https://clinicaltrials.gov/ct2/show/NCT01850160.

Keywords: Hypertension; chlorthalidone; combined therapy; monotherapy; valsartan.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interests:The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr. Juan Romero is a full-time employee of Farma. Dr. Carlos Rodriguez-Martinez has received partial compensation for statistical analysis. Data entry and statistical analyses were supported by Farma. Dr. Manzur and Dr. Rico report no potential conflict of interest relevant to this article.

Figures

Figure 1.
Figure 1.
Drug allocation and time for titration.
Figure 2.
Figure 2.
Flow chart of the participants, according to treatment group. BP: blood pressure; V: valsartan; C: chlorthalidone.
Figure 3.
Figure 3.
Changes in mean office SBP and DBP values from baseline to week 12, by study treatment group. SBP: systolic blood pressure; DBP: diastolic blood pressure; V: valsartan; C: chlorthalidone.
Figure 4.
Figure 4.
Mean change from baseline to week 12 in mean 24-h ambulatory systolic blood pressure monitoring, by study treatment group. ABPM SBP: 24-h ambulatory systolic blood pressure monitoring, V: valsartan, C: chlorthalidone.
Figure 5.
Figure 5.
Mean change from baseline to week 12 in mean 24-h ambulatory diastolic blood pressure monitoring, by study treatment group. ABPM DBP: 24-h ambulatory diastolic blood pressure monitoring; V: valsartan; C: chlorthalidone.
See this image and copyright information in PMC

References

    1. Forouzanfar M, Alexander L, Anderson H, et al. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:2287–2323. 10.1016/s0140-6736(15)00128-2. - DOI - PMC - PubMed
    1. Lawes C, Hoorn S, Rodgers A; International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet. 2008;371:1513–1518. 10.1016/s0140-6736(08)60655-8. - DOI - PubMed
    1. Mills K, Bundy J, Kelly T, et al. Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation. 2016;134:441–450. 10.1161/circulationaha.115.018912. - DOI - PMC - PubMed
    1. Informe técnico: Carga de enfermedad por enfermedades crónicas no transmisibles y discapacidad en Colombia. Instituto Nacional de Salud. 2015. https://www.minsalud.gov.co/sites/rid/Lists/BibliotecaDigital/RIDE/IA/IN.... Consultado September 8, 2017.
    1. Pereira M, Lunet N, Azevedo A, Barros H. Differences in prevalence, awareness, treatment and control of hypertension between developing and developed countries. J Hypertens. 2009;27:963–975. doi:10.1097/hjh.0b013e3283282f65. - DOI - PubMed

Associated data

LinkOut - more resources